MAPK3 and colon adenocarcinoma: This requirement of ERK1/2 is consistent with its requirement for colon adenocarcinoma (C26) conditioned media induced myotube atrophy and leukemia inhibitory factor-induced myotube atrophy [72], as well as cachexia in C26 tumor-bearing mice [39].